nu-verap sr tablet (extended-release)
nu-pharm inc - verapamil hydrochloride - tablet (extended-release) - 120mg - verapamil hydrochloride 120mg - miscellaneous calcium-channel blocking agents
prezcobix tablet
janssen inc - darunavir (darunavir ethanolate); cobicistat - tablet - 800mg; 150mg - darunavir (darunavir ethanolate) 800mg; cobicistat 150mg - hiv protease inhibitors
technivie tablet
abbvie corporation - ombitasvir; paritaprevir; ritonavir - tablet - 12.5mg; 75mg; 50mg - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg - hcv protease inhibitors
mylan-verapamil sr tablet (extended-release)
mylan pharmaceuticals ulc - verapamil hydrochloride - tablet (extended-release) - 120mg - verapamil hydrochloride 120mg - miscellaneous calcium-channel blocking agents
atripla- efavirenz, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated
a-s medication solutions - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - atripla® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. atripla is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to efavirenz, a component of atripla. coadminstration of atripla with voriconazole is contraindicated. efavirenz, a component of atripla, significantly decreases voriconazole plasma concentrations, and coadministration may decrease the therapeutic effectiveness of voriconazole. also, voriconazole significantly increases efavirenz plasma concentrations, which may increase the risk of efavirenz-associated side effects. because atripla is a fixed-dose combination product, the dose of efavirenz cannot be altered [see clinical pharmacology (12.3) tables 4 and 5]. pregnancy category d [see warnings and precautions (5.9)] antiret
symtuza tablet
janssen inc - darunavir (darunavir ethanolate); cobicistat; emtricitabine; tenofovir alafenamide (tenofovir alafenamide hemifumarate) - tablet - 800mg; 150mg; 200mg; 10mg - darunavir (darunavir ethanolate) 800mg; cobicistat 150mg; emtricitabine 200mg; tenofovir alafenamide (tenofovir alafenamide hemifumarate) 10mg - antiretrovirals
pms-efavirenz-emtricitabine-tenofovir tablet
pharmascience inc - efavirenz; emtricitabine; tenofovir disoproxil fumarate - tablet - 600mg; 200mg; 300mg - efavirenz 600mg; emtricitabine 200mg; tenofovir disoproxil fumarate 300mg - nonnucleoside reverse transcriptase inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 75mg - darunavir 75mg - hiv protease inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 150mg - darunavir 150mg - hiv protease inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 300mg - darunavir 300mg - hiv protease inhibitors